EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

Mahmut Emre Yildirim iD, Nuri Karadurmuş, İlker Nihat Ökten, Hacı Mehmet Türk, Zuhat Urakçı iD, Çağatay Arslan, Sinemis Çelik, Faysal Dane, Mehmet Ali Nahit Şendur iD, Cemil Bilir, Bülent Karabulut, İrfan Cicin iD und 17 weitere

Journal of Oncology Pharmacy Practice · 2025

DOI: 10.1177/10781552241241004 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Oncology Pharmacy Practice, 2025. Verfasst von Mahmut Emre Yildirim und 28 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, İstanbul Dr. Lütfi Kırdar Kartal City Hospital, Istanbu, Türkiye. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Biological Products, Colorectal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds and Objectives Colorectal cancer is one of the leading causes of mortality both globally and in our country. In Turkey, we conducted a multicenter investigation into the effectiveness of second-line treatments and real-life data for patients with RAS wild-type metastatic colorectal cancer (NCT04757311). Materials and Methods In this retrospective analysis, records from 28 centers were collected, and histopathological, molecular, and clinical characteristics were documented. Patients were categorized into groups based on their second-line biological treatments: anti-EGFR (Group A and Group B, panitumumab and cetuximab) and anti-VEGF (Group C, bevacizumab and aflibercept). They were then compared within these groups.

Results

A total of 588 patients with documented RAS wild-type status were evaluated. The median OS was 15.7, 14.3 and 14.7 months in Group A, Group B and Group C, respectively ( p = 0.764). The median PFS of the patients in second-line setting that received panitumumab, cetuximab and bevacizumab/aflibercept were 7.8, 6.6 and 7.4 months, respectively ( p = 0.848).

Conclusion

According to the results of our real-life data study, there is no significant difference in efficiency between the combination of biological agent and chemotherapy used in the second-line treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBiological ProductsColorectal NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedBevacizumabCetuximabErbB ReceptorsPanitumumabras ProteinsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRegistriesRetrospective StudiesTreatment OutcomeTurkey

Stichwörter der Autor:innen

Ras wild typecolon cancertargeted therapy

Substanzen

afliberceptBevacizumabBiological ProductsCetuximabErbB ReceptorsPanitumumabras ProteinsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Medical Oncology Department, İstanbul Dr. Lütfi Kırdar Kartal City Hospital, Istanbu, Türkiye.
  • Medical Oncology Department, Gulhane Training and Research Hospital, Ankara, Türkiye.
  • Medical Oncology Department, Medeniyet University Goztepe Training and Research Hospital, Istanbul, Türkiye.
  • Department of Medical Oncology, Bezmialem Vakif University Faculty of Medicine, Istanbul, Türkiye.
  • Department of Medical Oncology, Dicle University Medical Faculty, Diyarbakir, Türkiye.
  • Medical Oncology, Bahcesehir Universitesi Tip Fakultesi, Istanbul, Türkiye.

ORCID-Profile: Mahmut Emre Yildirim, Zuhat Urakçı, Mehmet Ali Nahit Şendur, İrfan Cicin, Erdem Çubukçu, Melike Ozcelik, Mehmet Artaç, Umut Kefeli, Deniz Tural, Abdullah Sakin

Zitieren

APA

Yildirim, M. E., Karadurmuş, N., Ökten, İ. N., Türk, H. M., Urakçı, Z., Arslan, Ç., Çelik, S., Dane, F., Şendur, M. A. N., Bilir, C., Karabulut, B., Cicin, İ., Çubukçu, E., Karaca, M., Ozcelik, M., Artaç, M., Tanrikulu, E., Alacacioglu, A., Açıkgöz, Ö., …, & Gumus, M. (2025). Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552241241004

Vancouver

Yildirim ME, Karadurmuş N, Ökten İN, Türk HM, Urakçı Z, Arslan Ç, et al. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC. Journal of Oncology Pharmacy Practice. 2025. doi:10.1177/10781552241241004

BibTeX
@article{Yildirim2025,
  author = {Yildirim, Mahmut Emre and Karadurmuş, Nuri and Ökten, İlker Nihat and Türk, Hacı Mehmet and Urakçı, Zuhat and Arslan, Çağatay and Çelik, Sinemis and Dane, Faysal and Şendur, Mehmet Ali Nahit and Bilir, Cemil and Karabulut, Bülent and Cicin, İrfan and Çubukçu, Erdem and Karaca, Mustafa and Ozcelik, Melike and Artaç, Mehmet and Tanrikulu, Eda and Alacacioglu, Ahmet and Açıkgöz, Özgür and Öven, Başak and Geredeli, Çağlayan and Çil, Timucin and Harputluoğlu, Hakan and Kefeli, Umut and Bozkurt, Oktay and Tural, Deniz and Sakin, Abdullah and Yalçın, Şuayip and Gumus, Mahmut},
  title = {Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC},
  journal = {Journal of Oncology Pharmacy Practice},
  year = {2025},
  doi = {10.1177/10781552241241004}
}
Kostenlos starten →